Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury.


Journal

Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615

Informations de publication

Date de publication:
02 2019
Historique:
received: 20 08 2018
accepted: 08 11 2018
pubmed: 15 11 2018
medline: 19 5 2020
entrez: 15 11 2018
Statut: ppublish

Résumé

The transcription factor NRF2, governed by its repressor KEAP1, protects cells against oxidative stress. There is interest in modelling the NRF2 response to improve the prediction of clinical toxicities such as drug-induced liver injury (DILI). However, very little is known about the makeup of the NRF2 transcriptional network and its response to chemical perturbation in primary human hepatocytes (PHH), which are often used as a translational model for investigating DILI. Here, microarray analysis identified 108 transcripts (including several putative novel NRF2-regulated genes) that were both downregulated by siRNA targeting NRF2 and upregulated by siRNA targeting KEAP1 in PHH. Applying weighted gene co-expression network analysis (WGCNA) to transcriptomic data from the Open TG-GATES toxicogenomics repository (representing PHH exposed to 158 compounds) revealed four co-expressed gene sets or 'modules' enriched for these and other NRF2-associated genes. By classifying the 158 TG-GATES compounds based on published evidence, and employing the four modules as network perturbation metrics, we found that the activation of NRF2 is a very good indicator of the intrinsic biochemical reactivity of a compound (i.e. its propensity to cause direct chemical stress), with relatively high sensitivity, specificity, accuracy and positive/negative predictive values. We also found that NRF2 activation has lower sensitivity for the prediction of clinical DILI risk, although relatively high specificity and positive predictive values indicate that false positive detection rates are likely to be low in this setting. Underpinned by our comprehensive analysis, activation of the NRF2 network is one of several mechanism-based components that can be incorporated into holistic systems toxicology models to improve mechanistic understanding and preclinical prediction of DILI in man.

Identifiants

pubmed: 30426165
doi: 10.1007/s00204-018-2354-1
pii: 10.1007/s00204-018-2354-1
pmc: PMC6373176
doi:

Substances chimiques

Isothiocyanates 0
KEAP1 protein, human 0
Kelch-Like ECH-Associated Protein 1 0
NF-E2-Related Factor 2 0
NFE2L2 protein, human 0
RNA, Small Interfering 0
Sulfoxides 0
sulforaphane GA49J4310U

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

385-399

Subventions

Organisme : Innovative Medicines Initiative
ID : 777365
Pays : International
Organisme : Medical Research Council
ID : MR/L006758/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700654
Pays : United Kingdom
Organisme : Innovative Medicines Initiative
ID : 116030
Pays : International
Organisme : Horizon 2020
ID : 681002
Pays : International
Organisme : Wellcome Trust
ID : 094128/Z/10/Z
Pays : United Kingdom
Organisme : European Molecular Biology Organization
ID : ASTF 398-2013
Pays : International

Références

Arch Toxicol. 2014 Dec;88(12):2261-87
pubmed: 25399406
Nat Rev Drug Discov. 2011 Apr;10(4):292-306
pubmed: 21455238
PLoS One. 2012;7(7):e39006
pubmed: 22808024
Arch Toxicol. 2018 May;92(5):1797-1814
pubmed: 29502165
Arch Toxicol. 2017 Mar;91(3):1367-1383
pubmed: 27358234
Methods Enzymol. 1996;272:388-401
pubmed: 8791798
PLoS Comput Biol. 2016 Mar 30;12(3):e1004847
pubmed: 27028627
Chem Res Toxicol. 2014 Mar 17;27(3):338-55
pubmed: 24450961
BMC Syst Biol. 2007 Nov 21;1:54
pubmed: 18031580
Nucleic Acids Res. 2012 Aug;40(15):7416-29
pubmed: 22581777
Drug Discov Today. 2016 Apr;21(4):648-53
pubmed: 26948801
Pharmacogenomics J. 2018 May 22;18(3):377-390
pubmed: 28440344
Expert Opin Drug Metab Toxicol. 2012 Feb;8(2):219-37
pubmed: 22248238
Nat Commun. 2016 Jan 26;7:10425
pubmed: 26811972
J Proteomics. 2014 Aug 28;108:171-87
pubmed: 24859727
Nucleic Acids Res. 2015 Jan;43(Database issue):D921-7
pubmed: 25313160
Arch Toxicol. 2017 Jan;91(1):439-452
pubmed: 27039104
J Proteomics. 2010 Jun 16;73(8):1612-31
pubmed: 20399915
Biochem Soc Trans. 2015 Aug;43(4):621-6
pubmed: 26551702
PLoS One. 2015 Feb 17;10(2):e0112655
pubmed: 25689681
Sci Rep. 2016 May 04;6:25187
pubmed: 27143246
Biochem Pharmacol. 2013 Mar 15;85(6):705-17
pubmed: 23219527
Toxicology. 2015 Oct 2;336:99-112
pubmed: 26215100
Nucl Recept Signal. 2015 Apr 27;13:e002
pubmed: 25949234
Stat Appl Genet Mol Biol. 2005;4:Article17
pubmed: 16646834
Front Genet. 2017 Oct 06;8:142
pubmed: 29085386
Mol Nutr Food Res. 2017 Apr;61(4):
pubmed: 27860235
Biomark Med. 2014;8(2):201-13
pubmed: 24521015
Biochem Soc Trans. 2015 Aug;43(4):611-20
pubmed: 26551701

Auteurs

Ian M Copple (IM)

MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK. ian.copple@liverpool.ac.uk.
Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institute, 171-77, Stockholm, Sweden. ian.copple@liverpool.ac.uk.

Wouter den Hollander (W)

Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC, Leiden, The Netherlands.

Giulia Callegaro (G)

Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC, Leiden, The Netherlands.

Fiona E Mutter (FE)

MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK.

James L Maggs (JL)

MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK.

Amy L Schofield (AL)

MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK.

Lucille Rainbow (L)

Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK.

Yongxiang Fang (Y)

Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK.

Jeffrey J Sutherland (JJ)

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA.

Ewa C Ellis (EC)

Liver Cell Lab, Unit for Transplantation Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska University Hospital Huddinge, 141-86, Stockholm, Sweden.

Magnus Ingelman-Sundberg (M)

Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institute, 171-77, Stockholm, Sweden.

Stephen W Fenwick (SW)

Department of Hepatobiliary Surgery, Aintree University Hospital NHS Foundation Trust, Liverpool, L9 7AL, UK.

Christopher E Goldring (CE)

MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK.

Bob van de Water (B)

Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC, Leiden, The Netherlands.

James L Stevens (JL)

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA.

B Kevin Park (BK)

MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH